Dr. Mazen Khalil, MD

Dr. Khalil practices at St. Bernards Medical Center in Jonesboro, Arkansas, part of St. Bernards Healthcare.

Dr. Khalil's NPI, 1659323608, was assigned on May 17, 2006. Dr. Khalil holds Arkansas license E-5722.

Dr. Khalil's primary practice is St. Bernards Medical Center, at 225 E Washington Ave, Jonesboro, AR 72401 in Craighead County. The practice phone is (870) 972-4100.

Dr. Khalil's primary practice is St. Bernards Medical Center in Jonesboro, Arkansas, part of St. Bernards Healthcare. Dr. Khalil is also affiliated with Baptist Memorial Hospital-Paragould. The medical group on file is St. Bernards Cancer Center. Dmand AI also links Dr. Khalil to 2 more hospitals, 1 group practice or clinic, 1 home health agency and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khalil practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khalil's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Khalil's licenses on file in 2 states: Arkansas and Tennessee.

CMS data shows 3,087 Medicare services from Dr. Khalil across 7 procedure codes in 2024, for 598 Medicare patients. Medicare paid $161,821 for them.

CMS counts 598 Medicare patients who saw Dr. Khalil in 2024. The largest group is 65 to 74, with 263 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khalil's median patient age at 65, with 63% women.

In 2024, Dr. Khalil wrote 2,227 Medicare Part D claims for 362 patients. 75% of them were for generic drugs. CMS names the drug for 1,943 of them, across 47 drugs with 11 or more claims each, at $6,062,169 in total drug cost. In 2023, CMS named 1,681 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 61 out of 100 for Dr. Khalil for performance year 2024, reported individually. Dr. Khalil accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Khalil, published from 2017 to 2024. 2017 was the busiest year, with 2. The most frequent topics are Antibodies, Monoclonal. Dr. Khalil has published most often in Cureus. Dr. Khalil's most frequent co-authors are Jennifer Effie Amengual, MD, Charles M. Farber, MD, PhD and Daruka Mahadevan, MD, PhD.

Dmand AI links Dr. Khalil to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Non-Small-Cell Lung. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Khalil that name 4 trials.

CMS Open Payments shows 1,591 general payments to Dr. Khalil from 81 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,573. It also lists 9 research payments totaling $13,906 from 2017 to 2020, naming 4 clinical trials.